EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

Ayumi Fujimoto iD, Wataru Munakata iD, Gakuto Ogawa, Ryunosuke Machida, Tomotaka Suzuki, Kazuyuki Shimada iD, Tsutomu Kobayashi iD, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama iD, Hirokazu Nagai

Cancer Science · 2025

DOI: 10.1111/cas.70304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Ayumi Fujimoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Shimane University, Izumo, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center Japan, Grants-in-Aid for Cancer Research, Ministry of Health, Labour, and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of achieving progression‐free survival at 24 months (PFS24) on subsequent survival in patients with diffuse large B‐cell lymphoma (DLBCL) relative to the general population remains debatable. We assessed the impact of achieving PFS24 in newly diagnosed DLBCL patients using data from JCOG0601, a prospective study of DLBCL patients treated with R‐CHOP. Among 409 eligible patients (median follow‐up: 5.3 years), 334 (82%) achieved PFS24, whereas 66 (16%) did not. Patients who achieved PFS24 had significantly better overall survival (OS) than those who did not (median OS, not reached vs. 1.3 years; p < 0.001). Similar results were observed for PFS12 and PFS60. The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55). Conversely, the OS for patients after achieving PFS12 was significantly worse than that of the general population (SMR 2.30, 95% CI 1.59–3.22, p < 0.001). The primary cause of death among patients who achieved PFS12 was DLBCL, whereas the mortality rate from DLBCL among those who achieved PFS24 or PFS60 was less than 5%. Multivariable analysis showed that having two or more extranodal involvements (OR 2.76 [95% CI 1.39–5.46], p = 0.004) was the only significant risk factor for failing to achieve PFS24. Our findings suggest that PFS24 can serve as an early endpoint of OS in patients with DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedPrednisoneDoxorubicinVincristineCyclophosphamideAdultRituximabProgression-Free SurvivalProspective StudiesAged, 80 and overAntibodies, Monoclonal, Murine-DerivedYoung Adult

Stichwörter der Autor:innen

diffuse large B‐cell lymphomaoverall survivalprognosisprogression‐free survivalrisk factors

Substanzen

PrednisoneDoxorubicinVincristineCyclophosphamideRituximabR-CHOP protocolAntibodies, Monoclonal, Murine-Derived

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Shimane University, Izumo, Japan.
  • Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • Japan Clinical Oncology Group Data Center, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.

ORCID-Profile: Ayumi Fujimoto, Wataru Munakata, Kazuyuki Shimada, Tsutomu Kobayashi, Dai Maruyama

Förderung

  • National Cancer Center Japan
  • Grants-in-Aid for Cancer Research
  • Ministry of Health, Labour, and Welfare

Zitieren

APA

Fujimoto, A., Munakata, W., Ogawa, G., Machida, R., Suzuki, T., Shimada, K., Kobayashi, T., Ohmachi, K., Kinoshita, T., Ando, K., Maruyama, D., & Nagai, H. (2025). Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients. Cancer Science. https://doi.org/10.1111/cas.70304

Vancouver

Fujimoto A, Munakata W, Ogawa G, Machida R, Suzuki T, Shimada K, et al. Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients. Cancer Science. 2025. doi:10.1111/cas.70304

BibTeX
@article{Fujimoto2025,
  author = {Fujimoto, Ayumi and Munakata, Wataru and Ogawa, Gakuto and Machida, Ryunosuke and Suzuki, Tomotaka and Shimada, Kazuyuki and Kobayashi, Tsutomu and Ohmachi, Ken and Kinoshita, Tomohiro and Ando, Kiyoshi and Maruyama, Dai and Nagai, Hirokazu},
  title = {Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70304}
}
Kostenlos starten →